Seeking Alpha

Triferic study chosen as best abstract at conference, Rockwell Medical rallies

  • Rockwell Medical (RMTI +9.7%) is having a strong session.
  • Helping the cause may be the announcement that a Triferic study (PRIME) was selected as best abstract submitted to the 34th Annual Dialysis Conference.
  • In PRIME, Triferic (when regularly administered) lowered ESA usage "while maintaining iron balance and maximizing iron delivery."
  • RMTI hopes that between PRIME and the CRUISE trials, there is enough evidence to show that Triferic can "establish a new paradigm in iron therapy treatment for hemodialysis patients." (PR)
  • A bit of controversy surrounding this issue flared up last month thanks to a negative note out of Brean.
Comments (2)
  • Brean should be investigated
    7 Jan, 02:08 PM Reply Like
  • Nice information
    7 Jan, 02:08 PM Reply Like
DJIA (DIA) S&P 500 (SPY)